News

Monitoring IOP pressure during sleeping hours, two doctors test it out for themselves

The American Society of Cataract and Refractive Surgery (ASCRS) is encouraging eye-care professionals to refer to presbyopia as age-related focus dysfunction.

Iridex Corp. has received a patent for its technology (MicroPulse) designed to provide ophthalmologists with fine dose control of laser energy during eye surgery in patients with glaucoma, diabetic retinopathy, and other retinal disorders.

A combined vitrectomy and phacoemulsification system (Stellaris Procedural Choice Vision Enhancement System, Bausch + Lomb) has been launched worldwide.

The FDA has issued a complete response letter regarding a new drug application (NDA) for oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis, according to the company.

The FDA ophthalmic devices panel supports the premarket approval of an implant (iStent Trabecular Micro-Bypass Stent Model GTS-100 L/R, Glaukos) for use in conjunction with cataract surgery to reduce IOP in patients with mild-to-moderate, open-angle glaucoma treated with ocular hypotensive medication.

Thomas G. Frinzi has been named WaveTec Vision?s president and chief executive officer.

Alcon Inc. has received regulatory approval of and has closed the acquisition of LenSx Lasers Inc.

Alcaftadine ophthalmic solution 0.25% (Lastacaft, Vistakon) has been approved by the FDA for the prevention of itching associated with allergic conjunctivitis in patients aged more than 2 years.

Novartis AG and Nestlé S.A. announced that they have completed the purchase and sale of about 156 million shares of Alcon Inc. $28.3 billion in cash.

With careful planning and surgical technique, phacoemulsification can be performed with good safety and efficacy outcomes in eyes with post-uveitic cataracts.

Inadequate cleansing of instruments and leftover enzyme and detergent residue are the primary culprits in outbreaks of toxic anterior segment syndrome.

Once upon a time-and not so long ago-eyeglasses were, well, glass.

A novel expanding lens glide holds promise to provide a useful addition to the cataract surgeon's armamentarium of techniques for managing cases involving a posterior capsule tear.

Two proprietary IOLs can provide good uncorrected distance visual acuity and reading performance in eyes of patients after bilateral IOL implantation.

The addition of chondroitin sulfate to ophthalmic viscosurgical devices has been a big plus, because it positively affects zero-shear viscosity.

Results from the 25th annual American Society of Cataract and Refractive Surgery Member Practice Style Survey show there is sustained growth in cataract surgery and use of specialty IOLs.

Results of a controlled clinical trial show that a software upgrade for performing torsional ultrasound with a proprietary handpiece and phaco system achieves its purpose of minimizing occlusion during phacoemulsification with consequences for improving the safety and efficiency of cataract removal.

Results of a study evaluating the performance of a new pressurized infusion system for a phaco platform show surgeons give it high ratings for ease of use and have a favorable impression of its efficacy for maintaining chamber stability.

When people are trained to sell, they are asked to consider carefully the words they choose to describe the products being offered.

Phacoemulsification technology has advanced steadily in the past decade, and the major phaco platforms available in the United States all are refined, highly efficacious systems.

The dilemma of selling multiple pairs of eyewear to our patients is that we may actually be sabotaging this effort ourselves.

Experience using a proprietary femtosecond laser with an integrated, real-time optical coherence tomography imaging device highlights the advantages provided by this technology in performing cataract surgery and its potential to raise the bar for functional and safety outcomes.

Over the past decade, prolific basic science and clinical research in all areas of vision care have led to multiple advances in clinical research.

Because of the versatility that 2.3% sodium hyaluronate provides, the author has used the ophthalmic viscosurgical device in every case for the past 5 years.

A combination ophthalmic viscosurgical device, 1.6% sodium hyaluronate, fills the bill during cataract surgery by combining the benefits of cohesive and dispersive agents in a single vial instead of two separate vials, making it more economical and simplifying surgery.

The author shares a favorite pasta dish and his reasons why he loves it.

ISTA Pharmaceuticals has initiated a phase I/II clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis.